The efficient commitment of a specialized cell type from induced pluripotent stem cells (iPSCs) without contamination from unknown substances is crucial to their use in clinical applications. Here, we propose that CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential, could be efficiently obtained from iPSCs derived from human bone marrow mesenchymal stem cells (hBMMSC-iPSCs) with defined factors. By treatment with a cocktail containing mesodermal, hematopoietic, and endothelial inducers (BMP4, SCF, and VEGF, respectively) for 5 days, hBMMSC-iPSCs expressed the mesodermal transcription factors Brachyury and GATA-2 at higher levels than untreated groups (P<0.05). After culturing with another hematopoietic and endothelial inducer cocktail, including SCF, Flt3L, VEGF and IL-3, for an additional 7–9 days, CD34+ progenitor cells, which were undetectable in the initial iPSC cultures, reached nearly 20% of the total culture. This was greater than the relative number of progenitor cells produced from human-skin-fibroblast-derived iPSCs (hFib-iPSCs) or from the spontaneous differentiation groups (P<0.05), as assessed by flow cytometry analysis. These induced cells expressed hematopoietic transcription factors TAL-1 and SCL. They developed into various hematopoietic colonies when exposed to semisolid media with hematopoietic cytokines such as EPO and G-CSF. Hematopoietic cell lineages were identified by phenotype analysis with Wright-Giemsa staining. The endothelial potential of the cells was also verified by the confirmation of the formation of vascular tube-like structures and the expression of endothelial-specific markers CD31 and VE-CADHERIN. Efficient induction of CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential with defined factors, provides an opportunity to obtain patient-specific cells for iPSC therapy and a useful model for the study of the mechanisms of hematopoiesis and drug screening.
References
[1]
Léger CS, Nevill TJ (2004) Hematopoietic stem cell transplantation: a primer for the primary care physician. CMAJ 170: 1569–1577.
[2]
K？rbling M, Anderlini P (2001) Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98: 2900–2908.
Hinterberger W, Hinterberger-Fischer M, Marmont A (2002) Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 30: 753–759.
[5]
Edward A, Copelan MD (2006) Hematopoietic Stem-Cell Transplantation. N Engl J Med 354: 1813–1826.
[6]
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. (1998) Embryonic Stem Cell Lines Derived from Human Blastocysts. Science 282: 1145–1147.
Keller G, Kennedy M, Papayannopoulou T, Wiles MV (1993) Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol 13: 473–486.
[9]
Vodyanik MA, Bork JA, Thomson JA, Slukvin II (2005) Human embryonic stem cells derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 105: 617–626.
[10]
Lu M, Kardel MD, O'Connor MD, Eaves CJ (2009) Enhanced generation of hematopoietic cells from human hepatocarcinoma cell-stimulated human embryonic and induced pluripotent stem cells. Exp Hematol 37: 924–936.
[11]
Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ (2005) Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci U S A 102: 19081–19086.
[12]
Nakano T, Kodama H, Honjo T (1996) In vitro development of primitive and definitive erythrocytes from different precursors. Science 5262: 722–724.
[13]
Zambidis ET, Peault B, Park TS, Bunz F, Civin CI (2005) Hematopoietic differentiation of human embryonic stem cells progresses through sequential hematoendothelial, primitive, and definitive stages resembling human yolk sac development. Blood 106: 860–870.
[14]
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676.
[15]
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Science 318: 1917–1920.
[16]
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872.
[17]
Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448: 313–317.
[18]
Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, et al. (2009) Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells. Stem Cells 27: 559–567.
[19]
Woods NB, Parker AS, Moraghebi R, Lutz MK, Firth AL, et al. (2011) Brief Report: Efficient Generation of Hematopoietic Precursors and Progenitors from Human Pluripotent Stem Cell Lines. Stem Cells 29: 1158–1164.
[20]
Chicha L, Feki A, Boni A, Irion O, Hovatta O, et al. (2011) Human Pluripotent Stem Cells Differentiated in Fully Defined Medium Generate Hematopoietic CD34- and CD34+ Progenitors with Distinct Characteristics. PLoS One 6: e14733.
[21]
Park SW, Jun Koh Y, Jeon J, Cho YH, Jang MJ, et al. (2010) Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways. Blood 116: 5762–5772.
[22]
Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G (2007) Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 109: 2679–2687.
[23]
Chadwick K, Wang L, Li L, Menendez P, Murdoch B, et al. (2003) Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 102: 906–915.
[24]
Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA (2001) Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 98: 10716–10721.
[25]
Cerdan C, Rouleau A, Bhatia M (2004) VEGF-A165 augments erythropoietic development from human embryonic stem cells. Blood 103: 2504–2512.
[26]
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science 284: 143–147.
[27]
Le Blanc K, Pittenger M (2005) Mesenchymal stem cells: progress toward promise. Cytotherapy 7: 36–45.
[28]
Niibe K, Kawamura Y, Araki D, Morikawa S, Miura K, et al. (2011) Purified Mesenchymal Stem Cells Are an Efficient Source for iPS Cell Induction. PLoS One 6: e17610.
[29]
Lengerke C, Grauer M, Niebuhr NI, Riedt T, Kanz L, et al. (2009) Hematopoietic development from human induced pluripotent stem cells. Ann N Y Acad Sci 1176: 219–227.
[30]
Pick M, Azzola L, Mossman A, Stanley EG, Elefanty AG (2007) Differentiation of Human Embryonic Stem Cells in Serum-Free Medium Reveals Distinct Roles for Bone Morphogenetic Protein 4, Vascular Endothelial Growth Factor, Stem Cell Factor, and Fibroblast Growth Factor 2 in Hematopoiesis. Stem Cells 25: 2206–2214.
[31]
Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, et al. (1993) Molecular cloning of a ligand for the tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 75: 1157–1167.
[32]
Murdoch B, Gallacher L, Chadwick K, Fellows F, Bhatia M (2002) Human embryonic-derived hematopoietic repopulating cells require distinct factors to sustain in vivo repopulating function. Exp Hematol 30: 598–605.
[33]
Tian X, Morris JK, Linehan JL, Kaufman DS (2004) Cytokine requirements differ for stroma and embryoid body-mediated hematopoiesis from human embryonic stem cells. Exp Hematol 32: 1000–1009.
[34]
Hassan HT, Zander A (1996) Stem cell factor as a survival and growth factor in human normal and malignant haemopoiesis. Acta Haematol 95: 257–262.
[35]
Feng Q, Lu SJ, Klimanskaya I, Gomes I, Kim D, et al. (2010) Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28: 704–712.
[36]
Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstr？m J, et al. (2008) Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 3: 85–98.
[37]
Qiu C, Hanson E, Olivier E, Inada M, Kaufman DS, et al. (2005) Differentiation of human embryonic stem cells into hematopoietic cells by coculture with human fetal liver cells recapitulates the globin switch that occurs early in development. Exp Hematol 33: 1450–1458.
[38]
Szabo E, Rampalli S, Risue？o RM, Schnerch A, Mitchell R, et al. (2010) Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 468: 521–526.
[39]
Seiler K, Soroush Noghabi M, Karjalainen K, Hummel M, Melchers F, et al. (2011) Induced Pluripotent Stem Cells Expressing Elevated Levels of Sox-2, Oct-4, and Klf-4 Are Severely Reduced in Their Differentiation from Mesodermal to Hematopoietic Progenitor Cells. Stem Cells Dev 20: 1131–1142.
[40]
Zhao YM, Li JY, Lan JP, Lai XY, Luo Y, et al. (2008) Cell cycle dependent telomere regulation by telomerase in human bone marrow mesenchymal stem cells. Biochem Biophys Res Commun 369: 1114–1119.
